Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients. The current project aims to determine the benefit of the introduction of these new t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangana, Joanna, Cheng, Phil F., Kaufmann, Corina, Amann, Valerie C., Frauchiger, Anna L., Stögner, Viola, Held, Ulrike, von Moos, Roger, Michielin, Olivier, Braun, Ralph P., Levesque, Mitchell P., Goldinger, Simone M., Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
ORIGINAL ARTICLES: Clinical research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633326/
https://www.ncbi.nlm.nih.gov/pubmed/28509765
http://dx.doi.org/10.1097/CMR.0000000000000359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633326/
https://www.ncbi.nlm.nih.gov/pubmed/28509765
http://dx.doi.org/10.1097/CMR.0000000000000359

Ejemplares similares